The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Mar. 24, 2015

Filed:

Feb. 12, 2011
Applicants:

Barry G. W. Arnason, Chicago, IL (US);

Mark A. Jensen, Chicago, IL (US);

David M. White, Chicago, IL (US);

Inventors:

Barry G. W. Arnason, Chicago, IL (US);

Mark A. Jensen, Chicago, IL (US);

David M. White, Chicago, IL (US);

Assignee:

Iterative Therapeutics, Inc., Chicago, IL (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 39/00 (2006.01); A61K 39/38 (2006.01); A61K 39/395 (2006.01); C07K 16/28 (2006.01); C07K 16/00 (2006.01); C07K 14/765 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2815 (2013.01); A61K 2039/505 (2013.01); C07K 16/00 (2013.01); C07K 2317/21 (2013.01); C07K 2317/53 (2013.01); C07K 2317/74 (2013.01); C07K 2319/00 (2013.01); C07K 2319/30 (2013.01); C07K 2317/64 (2013.01); C07K 2317/52 (2013.01); C07K 14/765 (2013.01);
Abstract

The present invention concerns a family of nucleic acids, polypeptides and cloning vectors which direct expression of fusion proteins that can mimic aggregated IgG (AIG) and immune complex function with respect to their interactions with FcγR and which allow for the inclusion and targeting of a second protein domain to cells expressing FcγR. This was accomplished by expressing multiple linear copies of the hinge and CH2 domains (HCH2) of human IgGfused to the framework region of human IgG. Convenient restriction sites allow for the facile introduction of additional amino-terminal domains. Methods for treating patients using fusion proteins are also disclosed. The HCH2 polymers described here represent a new strategy in the design of recombinant proteins for the therapeutic targeting of FcγR in autoimmune disorders.


Find Patent Forward Citations

Loading…